Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert

Effect of brimonidine tartrate 0.2% ophthalmic solution on visual quality after implantable collamer lens implantation with a central hole

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Phakic IOLs III

Session Date/Time: Tuesday 13/09/2016 | 09:30-11:00

Paper Time: 10:10

Venue: Poster Village: Pod 4

First Author: : X.Wang CHINA

Co Author(s): :    X. Chen   X. Zhou           

Abstract Details


To investigate the effect of brimonidine tartrate 0.2% ophthalmic solution (Alphagan)on visual quality after Implantable Collamer Lens implantation with a central hole (ICL V4c).


The Department of Ophthalmology,Eye& ENT Hospital of Fudan University, Shanghai, China


This study comprised 59 consecutive patients who implanted ICL V4c. Alphaganwas administered randomly in one eye of 21 patients with symptomatic glares/halos 1 week postoperatively, visual quality, pupil size and refraction under scotopiclight conditions were measured before and 0.5h, 1.5h, 3h, 6h after administration, respectively. Questionnaire was also evaluated.


The visual quality improved and reached high point 1.5h after alphaganadministration, meanwhile, the scotopic pupil was the smallest, and a significant statistical difference was seen between 1.5h and baseline; then the visual quality parameters gradually restored to baseline after 1.5h, but the visual quality was still better than that of contralateral eye after 6h. No change in refraction was seen after alphagan. The questionnaire showed that glares/halos could be eliminated after alphagan in some patients, be alleviated in most patients and be unchanged only in a minority of patients. But drug efficacy rebounded, 9.52% patients might have conjunctival congestion and some patients experienced a weaken efficacy 1 month after treatment.


Alphagan can be used to improve night visual quality in the early time after ICL V4c implantation. It helps patients to quickly adapt to the glares/halos and has a long therapeutic time.

Financial Disclosure:


Back to previous